Europe Approves Exblifep for UTIs and Pneumonia

Exblifep is as effective as piperacillin-tazobactam in the treatment of complicated urinary tract infections, the European Medicines Agency said.

Related Keywords

,Committee For Medicinal Products Human Use ,European Medicines Agency ,Medicinal Products ,Human Use ,Followed Phase ,Urinary Tract Infection Uti ,Europe ,European ,Pneumonia ,Mechanical Ventilation ,Pyelonephritis ,Hospitals ,Antibacterial ,Acteriocide ,Actericide ,Patient Safety ,Ventilator Associated Pneumonia ,Adverse Effects ,Side Effects ,Bacteremia Bacteraemia ,Clinical Research ,Clinical Trials ,Linical Studies ,Pre Clinical Trial ,Double Blind Study ,Double Blind Studies ,